Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According to the announcement, Strides will manufacture the nasal sprays at its facility in Chestnut Ridge, NY, USA and intends to commercialize the products in the US and Europe, as well as some additional markets.
Strides notes that it acquired the Chestnut Ridge facility from Endo in October 2021 and that the plant “has comprehensive capabilities for nasal spray manufacturing in the unit dose and multi-dose format, including for controlled substances.” Orbicular focuses on the development of complex products, including products for inhalation.
Read the Strides Pharma Science press release.
